14,15-CYCLOPROPANOSTEROIDE DER 19-NORANDROSTAN-REIHE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
    7.
    发明公开
    14,15-CYCLOPROPANOSTEROIDE DER 19-NORANDROSTAN-REIHE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN 有权
    14,15-CYCLOPROPANOSTEROIDE DER 19-NORANDROSTAN-REIHE,VERFAHREN ZU IHRER HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZUUTISCHE ZUSAMMENSETZUNGEN

    公开(公告)号:EP1242445A1

    公开(公告)日:2002-09-25

    申请号:EP00988735.7

    申请日:2000-11-21

    CPC分类号: C07J53/004

    摘要: The invention relates to novel 14,15-cyclopropanosteroids of the 19-norandrostane series having the general formula (I), preparation thereof and pharmaceutical compositions containing said compounds. Compounds of the formula (I) have an interesting androgen/gestagen mixture profile. The activity of the androgens or the gestagens can predominate, depending on the respective substitution.

    摘要翻译: 本发明涉及具有通式(I)的19-去甲基雄甾烷系列的新型14,15-环丙烷类固醇,其制备和含有该化合物的药物组合物。 式(I)化合物具有令人感兴趣的雄激素/孕激素混合物特征。 取决于各自的取代,雄激素或孕激素的活性可占主导地位。

    MESOPROGESTINS FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE DEPENDENT GYNECOLOGICAL DISORDERS
    8.
    发明公开
    MESOPROGESTINS FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE DEPENDENT GYNECOLOGICAL DISORDERS 有权
    Mesoprogestins用于治疗和预防激素依赖性良性妇科疾患

    公开(公告)号:EP1229906A2

    公开(公告)日:2002-08-14

    申请号:EP00957914.5

    申请日:2000-08-31

    CPC分类号: A61K31/57 A61K45/06

    摘要: This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoprogestin. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. The daily dose of mesoprogestin is 0.5 to 100 mg, preferably 5.0 to 50 mg and most preferably 10 to 25 mg. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.

    15-METHYL-CYCLOPROPANOSTEROIDE UND VERFHAREN ZU IHRER HERSTELLUNG

    公开(公告)号:EP1056769B1

    公开(公告)日:2002-06-19

    申请号:EP98965592.3

    申请日:1998-11-30

    IPC分类号: C07J53/00 A61K31/565

    CPC分类号: C07J53/004

    摘要: The invention relates to novel 15-methyl-cyclopropanosteroids of general formula (I), wherein R1 represents a hydrogen atom, an alkyl group, an acyl group, or a sulfamoyl group, R2 and R3 represent independently from each other a hydrogen atom or a halogen atom, R4 represents an oxo group or a hydrogen atom and a hydroxy group, and the 14,15-methylene group has either an alpha or beta configuration, wherein the 15-methyl group is in beta position when the 14,15-methylene group is arranged in alpha position and vice-versa. The invention also relates to 15 methyl-pentasteroids which are suitable as parent compounds in the production of the inventive 15-methyl-cyclopropanosteroids. The invention further relates to a method for the production of the inventive 15-methyl-cyclopropanosteroids and 15-methylpentaensteroids.

    摘要翻译: 本发明涉及新颖的通式(I),其中R1表示氢原子,烷基,酰基,或氨磺酰基,R2和R3彼此氢原子或独立地表示15甲基cyclopropanosteroids 卤原子,R 4表示氧代基团或氢原子和羟基,以及14,15-亚甲基组具有α或β构型,其中15-甲基是在β位当14,15-亚甲基 组排列在alpha位置,反之亦然。 本发明还涉及在制备本发明的15-甲基 - 环丙烷类固醇时适合作为母体化合物的15种甲基 - 五溴甾体。 本发明进一步涉及用于生产本发明的15-甲基 - 环丙烷类固醇和15-甲基戊五萜类的方法。